CA2893318A1 - Thienopyridine derivatives for the treatment and prevention of dengue virus infections - Google Patents
Thienopyridine derivatives for the treatment and prevention of dengue virus infections Download PDFInfo
- Publication number
- CA2893318A1 CA2893318A1 CA2893318A CA2893318A CA2893318A1 CA 2893318 A1 CA2893318 A1 CA 2893318A1 CA 2893318 A CA2893318 A CA 2893318A CA 2893318 A CA2893318 A CA 2893318A CA 2893318 A1 CA2893318 A1 CA 2893318A1
- Authority
- CA
- Canada
- Prior art keywords
- amino
- thieno
- pyridine
- carboxamide
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 26
- 206010012310 Dengue fever Diseases 0.000 title claims description 94
- 208000025729 dengue disease Diseases 0.000 title claims description 76
- 230000002265 prevention Effects 0.000 title description 3
- DBDCNCCRPKTRSD-UHFFFAOYSA-N thieno[3,2-b]pyridine Chemical class C1=CC=C2SC=CC2=N1 DBDCNCCRPKTRSD-UHFFFAOYSA-N 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 214
- -1 thienopyridine derivative compounds Chemical class 0.000 claims abstract description 119
- 238000000034 method Methods 0.000 claims abstract description 89
- 241000725619 Dengue virus Species 0.000 claims abstract description 33
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 28
- 230000009385 viral infection Effects 0.000 claims abstract description 9
- 208000036142 Viral infection Diseases 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims description 145
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 111
- 125000003118 aryl group Chemical group 0.000 claims description 93
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 84
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 81
- 125000001072 heteroaryl group Chemical group 0.000 claims description 79
- 208000001490 Dengue Diseases 0.000 claims description 65
- 125000000217 alkyl group Chemical group 0.000 claims description 54
- 239000001257 hydrogen Substances 0.000 claims description 49
- 229910052739 hydrogen Inorganic materials 0.000 claims description 49
- 125000002252 acyl group Chemical group 0.000 claims description 45
- 125000003342 alkenyl group Chemical group 0.000 claims description 45
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 45
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 42
- 125000005251 aryl acyl group Chemical group 0.000 claims description 42
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 42
- 125000005170 cycloalkyloxycarbonyl group Chemical group 0.000 claims description 42
- 125000005253 heteroarylacyl group Chemical group 0.000 claims description 42
- 125000000304 alkynyl group Chemical group 0.000 claims description 41
- 150000003839 salts Chemical class 0.000 claims description 41
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 34
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 34
- 208000009714 Severe Dengue Diseases 0.000 claims description 32
- 229910052757 nitrogen Inorganic materials 0.000 claims description 29
- 229910052799 carbon Inorganic materials 0.000 claims description 26
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 24
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 23
- 125000005241 heteroarylamino group Chemical group 0.000 claims description 22
- 125000004442 acylamino group Chemical group 0.000 claims description 21
- 125000001769 aryl amino group Chemical group 0.000 claims description 21
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 21
- 201000002950 dengue hemorrhagic fever Diseases 0.000 claims description 21
- 125000005842 heteroatom Chemical group 0.000 claims description 21
- 241000124008 Mammalia Species 0.000 claims description 20
- 125000003282 alkyl amino group Chemical group 0.000 claims description 20
- 229910052736 halogen Inorganic materials 0.000 claims description 20
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 19
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 claims description 19
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims description 19
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 19
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 19
- 229960005486 vaccine Drugs 0.000 claims description 18
- 125000001931 aliphatic group Chemical group 0.000 claims description 17
- 125000004104 aryloxy group Chemical group 0.000 claims description 15
- 241001465754 Metazoa Species 0.000 claims description 14
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 14
- 125000004423 acyloxy group Chemical group 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 12
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 11
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 11
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 claims description 11
- 125000004414 alkyl thio group Chemical group 0.000 claims description 11
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims description 11
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 11
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 claims description 11
- 125000005110 aryl thio group Chemical group 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 11
- 125000005843 halogen group Chemical group 0.000 claims description 11
- 125000002462 isocyano group Chemical group *[N+]#[C-] 0.000 claims description 11
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 11
- 229910052717 sulfur Inorganic materials 0.000 claims description 11
- XNTAESPDXNOSPE-UHFFFAOYSA-N 3-amino-n,6-bis(4-chlorophenyl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=1C=C2C(N)=C(C(=O)NC=3C=CC(Cl)=CC=3)SC2=NC=1C1=CC=C(Cl)C=C1 XNTAESPDXNOSPE-UHFFFAOYSA-N 0.000 claims description 10
- 239000003443 antiviral agent Substances 0.000 claims description 10
- FXTSYHIBGLLDBP-UHFFFAOYSA-N 4-[[3-amino-6-(4-chlorophenyl)thieno[2,3-b]pyridine-2-carbonyl]amino]benzenesulfonic acid Chemical compound C=1C=C2C(N)=C(C(=O)NC=3C=CC(=CC=3)S(O)(=O)=O)SC2=NC=1C1=CC=C(Cl)C=C1 FXTSYHIBGLLDBP-UHFFFAOYSA-N 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- CFRWNHJFWJWWDG-UHFFFAOYSA-N 3-amino-6-(trifluoromethyl)-n-[3-(trifluoromethyl)phenyl]thieno[2,3-b]pyridine-2-carboxamide Chemical compound S1C2=NC(C(F)(F)F)=CC=C2C(N)=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 CFRWNHJFWJWWDG-UHFFFAOYSA-N 0.000 claims description 8
- 102000014150 Interferons Human genes 0.000 claims description 8
- 108010050904 Interferons Proteins 0.000 claims description 8
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 8
- JZGXAEVJGRCVBU-UHFFFAOYSA-N 4-[[3-amino-6-(4-chlorophenyl)thieno[2,3-b]pyridine-2-carbonyl]amino]benzoic acid Chemical compound C=1C=C2C(N)=C(C(=O)NC=3C=CC(=CC=3)C(O)=O)SC2=NC=1C1=CC=C(Cl)C=C1 JZGXAEVJGRCVBU-UHFFFAOYSA-N 0.000 claims description 6
- MCDIZEGYBFVWOK-UHFFFAOYSA-N 3,5-diamino-n-(5-phenyl-1,3,4-thiadiazol-2-yl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound S1C2=NC=C(N)C=C2C(N)=C1C(=O)NC(S1)=NN=C1C1=CC=CC=C1 MCDIZEGYBFVWOK-UHFFFAOYSA-N 0.000 claims description 5
- KMZMTCNWFUJBNJ-UHFFFAOYSA-N 3-amino-6-chloro-n-(5-phenyl-1,3,4-thiadiazol-2-yl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound S1C2=NC(Cl)=CC=C2C(N)=C1C(=O)NC(S1)=NN=C1C1=CC=CC=C1 KMZMTCNWFUJBNJ-UHFFFAOYSA-N 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- NDGVXZHIZIUDQQ-UHFFFAOYSA-N 3-amino-2-[(5-phenyl-1,3,4-thiadiazol-2-yl)carbamoyl]thieno[2,3-b]pyridine-5-carboxylic acid Chemical compound S1C2=NC=C(C(O)=O)C=C2C(N)=C1C(=O)NC(S1)=NN=C1C1=CC=CC=C1 NDGVXZHIZIUDQQ-UHFFFAOYSA-N 0.000 claims description 4
- 238000011260 co-administration Methods 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims 10
- SNFGEKZZSGJGBG-UHFFFAOYSA-N 3-[n-(3-amino-6-thiophen-2-ylthieno[2,3-b]pyridine-2-carbonyl)-3-(trifluoromethyl)anilino]propanoic acid Chemical compound C=1C=C2C(N)=C(C(=O)N(CCC(O)=O)C=3C=C(C=CC=3)C(F)(F)F)SC2=NC=1C1=CC=CS1 SNFGEKZZSGJGBG-UHFFFAOYSA-N 0.000 claims 6
- HYYKFLNLVBEYPL-UHFFFAOYSA-N 3-amino-6-[3-(difluoromethoxy)phenyl]-n-[4-(difluoromethoxy)phenyl]thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=1C=C2C(N)=C(C(=O)NC=3C=CC(OC(F)F)=CC=3)SC2=NC=1C1=CC=CC(OC(F)F)=C1 HYYKFLNLVBEYPL-UHFFFAOYSA-N 0.000 claims 6
- 229940079322 interferon Drugs 0.000 claims 6
- JPNLDJUBHQCXBA-UHFFFAOYSA-N 3-amino-6-(3-methoxyphenyl)-n-[4-(trifluoromethoxy)phenyl]thieno[2,3-b]pyridine-2-carboxamide Chemical compound COC1=CC=CC(C=2N=C3SC(=C(N)C3=CC=2)C(=O)NC=2C=CC(OC(F)(F)F)=CC=2)=C1 JPNLDJUBHQCXBA-UHFFFAOYSA-N 0.000 claims 4
- MPYDTAKQTJCYMA-UHFFFAOYSA-N 3-amino-n-(4-bromophenyl)-6-(4-chlorophenyl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=1C=C2C(N)=C(C(=O)NC=3C=CC(Br)=CC=3)SC2=NC=1C1=CC=C(Cl)C=C1 MPYDTAKQTJCYMA-UHFFFAOYSA-N 0.000 claims 4
- LCFGVXANCKUZJX-UHFFFAOYSA-N 2-[n-(3-amino-6-thiophen-2-ylthieno[2,3-b]pyridine-2-carbonyl)-3-(trifluoromethyl)anilino]acetic acid Chemical compound C=1C=C2C(N)=C(C(=O)N(CC(O)=O)C=3C=C(C=CC=3)C(F)(F)F)SC2=NC=1C1=CC=CS1 LCFGVXANCKUZJX-UHFFFAOYSA-N 0.000 claims 3
- IPXYPQNRIHCBBT-UHFFFAOYSA-N 2-thiophen-2-yl-10-[3-(trifluoromethyl)phenyl]-7,8-dihydro-5h-pyrido[2,3]thieno[2,4-d][1,5]diazonine-6,9,11-trione Chemical compound FC(F)(F)C1=CC=CC(N2C(C3=C(C4=CC=C(N=C4S3)C=3SC=CC=3)NC(=O)CCC2=O)=O)=C1 IPXYPQNRIHCBBT-UHFFFAOYSA-N 0.000 claims 3
- VUKUIZBMXWMXFX-UHFFFAOYSA-N 3-(n-[3-amino-6-(4-chlorophenyl)thieno[2,3-b]pyridine-2-carbonyl]-4-bromoanilino)propanoic acid Chemical compound C=1C=C2C(N)=C(C(=O)N(CCC(O)=O)C=3C=CC(Br)=CC=3)SC2=NC=1C1=CC=C(Cl)C=C1 VUKUIZBMXWMXFX-UHFFFAOYSA-N 0.000 claims 3
- FQJQNKYIZYNAHZ-UHFFFAOYSA-N 3-(n-[3-amino-6-(4-chlorophenyl)thieno[2,3-b]pyridine-2-carbonyl]-4-chloroanilino)propanoic acid Chemical compound C=1C=C2C(N)=C(C(=O)N(CCC(O)=O)C=3C=CC(Cl)=CC=3)SC2=NC=1C1=CC=C(Cl)C=C1 FQJQNKYIZYNAHZ-UHFFFAOYSA-N 0.000 claims 3
- HOKLVNXVCQSSAN-UHFFFAOYSA-N 3-[n-[3-amino-6-(3-methoxyphenyl)thieno[2,3-b]pyridine-2-carbonyl]-4-(trifluoromethoxy)anilino]propanoic acid Chemical compound COC1=CC=CC(C=2N=C3SC(=C(N)C3=CC=2)C(=O)N(CCC(O)=O)C=2C=CC(OC(F)(F)F)=CC=2)=C1 HOKLVNXVCQSSAN-UHFFFAOYSA-N 0.000 claims 3
- MXLZVYYKPDMFBB-UHFFFAOYSA-N 3-amino-4-methoxy-n-(5-phenyl-1,3,4-thiadiazol-2-yl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound NC=1C=2C(OC)=CC=NC=2SC=1C(=O)NC(S1)=NN=C1C1=CC=CC=C1 MXLZVYYKPDMFBB-UHFFFAOYSA-N 0.000 claims 3
- QXUIHCAEJBKALB-UHFFFAOYSA-N 3-amino-4-methyl-n-(5-phenyl-1,3,4-thiadiazol-2-yl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound NC=1C=2C(C)=CC=NC=2SC=1C(=O)NC(S1)=NN=C1C1=CC=CC=C1 QXUIHCAEJBKALB-UHFFFAOYSA-N 0.000 claims 3
- ZGMWBQBYKMJQOB-UHFFFAOYSA-N 3-amino-5-hydroxy-n-(5-phenyl-1,3,4-thiadiazol-2-yl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]thieno[3,2-e]pyridine-2-carboxamide Chemical compound S1C2=NC=3CCCCC(O)C=3C=C2C(N)=C1C(=O)NC(S1)=NN=C1C1=CC=CC=C1 ZGMWBQBYKMJQOB-UHFFFAOYSA-N 0.000 claims 3
- YAMPVXYBSZVZNL-UHFFFAOYSA-N 3-amino-5-methyl-n-(5-phenyl-1,3,4-thiadiazol-2-yl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound NC=1C2=CC(C)=CN=C2SC=1C(=O)NC(S1)=NN=C1C1=CC=CC=C1 YAMPVXYBSZVZNL-UHFFFAOYSA-N 0.000 claims 3
- CKYUFAYVYUXPJA-UHFFFAOYSA-N 3-amino-5-oxo-n-(5-phenyl-1,3,4-thiadiazol-2-yl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]thieno[3,2-e]pyridine-2-carboxamide Chemical compound S1C2=NC=3CCCCC(=O)C=3C=C2C(N)=C1C(=O)NC(S1)=NN=C1C1=CC=CC=C1 CKYUFAYVYUXPJA-UHFFFAOYSA-N 0.000 claims 3
- MDMFZCQYRTZOBG-UHFFFAOYSA-N 3-amino-6-(2,4-dimethyl-1,3-thiazol-5-yl)-n-[3-(trifluoromethyl)phenyl]thieno[2,3-b]pyridine-2-carboxamide Chemical compound S1C(C)=NC(C)=C1C1=CC=C(C(N)=C(S2)C(=O)NC=3C=C(C=CC=3)C(F)(F)F)C2=N1 MDMFZCQYRTZOBG-UHFFFAOYSA-N 0.000 claims 3
- LHSDGLRNODSUHS-UHFFFAOYSA-N 3-amino-6-(4-chlorophenyl)-n-(2,3-dichlorophenyl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=1C=C2C(N)=C(C(=O)NC=3C(=C(Cl)C=CC=3)Cl)SC2=NC=1C1=CC=C(Cl)C=C1 LHSDGLRNODSUHS-UHFFFAOYSA-N 0.000 claims 3
- MPLAXMJMWCHYCS-UHFFFAOYSA-N 3-amino-6-(4-chlorophenyl)-n-(2,5-dichlorophenyl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=1C=C2C(N)=C(C(=O)NC=3C(=CC=C(Cl)C=3)Cl)SC2=NC=1C1=CC=C(Cl)C=C1 MPLAXMJMWCHYCS-UHFFFAOYSA-N 0.000 claims 3
- JYNJRAVEYDAEIM-UHFFFAOYSA-N 3-amino-6-(4-chlorophenyl)-n-(3,4-dichlorophenyl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=1C=C2C(N)=C(C(=O)NC=3C=C(Cl)C(Cl)=CC=3)SC2=NC=1C1=CC=C(Cl)C=C1 JYNJRAVEYDAEIM-UHFFFAOYSA-N 0.000 claims 3
- AIRAIJSHUNKACH-UHFFFAOYSA-N 3-amino-6-(4-chlorophenyl)-n-(3,4-dimethylphenyl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C1=C(C)C(C)=CC=C1NC(=O)C1=C(N)C2=CC=C(C=3C=CC(Cl)=CC=3)N=C2S1 AIRAIJSHUNKACH-UHFFFAOYSA-N 0.000 claims 3
- SCIZKGYHKPMVJA-UHFFFAOYSA-N 3-amino-6-(4-chlorophenyl)-n-(4-hydroxyphenyl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=1C=C2C(N)=C(C(=O)NC=3C=CC(O)=CC=3)SC2=NC=1C1=CC=C(Cl)C=C1 SCIZKGYHKPMVJA-UHFFFAOYSA-N 0.000 claims 3
- VBNGRQWGAKKUNY-UHFFFAOYSA-N 3-amino-6-(4-chlorophenyl)-n-(5-chloropyridin-2-yl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=1C=C2C(N)=C(C(=O)NC=3N=CC(Cl)=CC=3)SC2=NC=1C1=CC=C(Cl)C=C1 VBNGRQWGAKKUNY-UHFFFAOYSA-N 0.000 claims 3
- GVLWWNSSPZCFPO-UHFFFAOYSA-N 3-amino-6-(4-chlorophenyl)-n-(6-chloropyridin-3-yl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=1C=C2C(N)=C(C(=O)NC=3C=NC(Cl)=CC=3)SC2=NC=1C1=CC=C(Cl)C=C1 GVLWWNSSPZCFPO-UHFFFAOYSA-N 0.000 claims 3
- QHEFGRKZJVYUNP-UHFFFAOYSA-N 3-amino-6-(4-chlorophenyl)-n-[4-(1,1-difluoroethyl)phenyl]thieno[2,3-b]pyridine-2-carboxamide Chemical compound C1=CC(C(F)(F)C)=CC=C1NC(=O)C1=C(N)C2=CC=C(C=3C=CC(Cl)=CC=3)N=C2S1 QHEFGRKZJVYUNP-UHFFFAOYSA-N 0.000 claims 3
- RYXOLLQLNXXYKS-UHFFFAOYSA-N 3-amino-6-(4-chlorophenyl)-n-[4-(2,2,2-trifluoroacetyl)phenyl]thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=1C=C2C(N)=C(C(=O)NC=3C=CC(=CC=3)C(=O)C(F)(F)F)SC2=NC=1C1=CC=C(Cl)C=C1 RYXOLLQLNXXYKS-UHFFFAOYSA-N 0.000 claims 3
- QNRUSQOBAHFIEE-UHFFFAOYSA-N 3-amino-6-(4-chlorophenyl)-n-[4-(difluoromethoxy)phenyl]thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=1C=C2C(N)=C(C(=O)NC=3C=CC(OC(F)F)=CC=3)SC2=NC=1C1=CC=C(Cl)C=C1 QNRUSQOBAHFIEE-UHFFFAOYSA-N 0.000 claims 3
- ZODGXOCXCDWHMX-UHFFFAOYSA-N 3-amino-6-(4-chlorophenyl)-n-[4-(difluoromethyl)phenyl]thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=1C=C2C(N)=C(C(=O)NC=3C=CC(=CC=3)C(F)F)SC2=NC=1C1=CC=C(Cl)C=C1 ZODGXOCXCDWHMX-UHFFFAOYSA-N 0.000 claims 3
- HNJZUZAOXQXPRI-UHFFFAOYSA-N 3-amino-6-(4-chlorophenyl)-n-[4-(trifluoromethoxy)phenyl]thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=1C=C2C(N)=C(C(=O)NC=3C=CC(OC(F)(F)F)=CC=3)SC2=NC=1C1=CC=C(Cl)C=C1 HNJZUZAOXQXPRI-UHFFFAOYSA-N 0.000 claims 3
- CUMDBGFMCPBWQP-UHFFFAOYSA-N 3-amino-6-[3-(difluoromethoxy)phenyl]-n-[4-(trifluoromethoxy)phenyl]thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=1C=C2C(N)=C(C(=O)NC=3C=CC(OC(F)(F)F)=CC=3)SC2=NC=1C1=CC=CC(OC(F)F)=C1 CUMDBGFMCPBWQP-UHFFFAOYSA-N 0.000 claims 3
- WVNUJGBJACCANV-UHFFFAOYSA-N 3-amino-6-[3-(trifluoromethoxy)phenyl]-n-[4-(trifluoromethoxy)phenyl]thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=1C=C2C(N)=C(C(=O)NC=3C=CC(OC(F)(F)F)=CC=3)SC2=NC=1C1=CC=CC(OC(F)(F)F)=C1 WVNUJGBJACCANV-UHFFFAOYSA-N 0.000 claims 3
- UKHXBJBAFYSLDS-UHFFFAOYSA-N 3-amino-6-methyl-n-(5-phenyl-1,3,4-thiadiazol-2-yl)-7,8-dihydro-5h-thieno[2,3-b][1,6]naphthyridine-2-carboxamide Chemical compound NC=1C=2C=C3CN(C)CCC3=NC=2SC=1C(=O)NC(S1)=NN=C1C1=CC=CC=C1 UKHXBJBAFYSLDS-UHFFFAOYSA-N 0.000 claims 3
- HHYFXDUSKRMHCQ-UHFFFAOYSA-N 3-amino-6-methyl-n-(5-phenyl-1,3,4-thiadiazol-2-yl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound S1C2=NC(C)=CC=C2C(N)=C1C(=O)NC(S1)=NN=C1C1=CC=CC=C1 HHYFXDUSKRMHCQ-UHFFFAOYSA-N 0.000 claims 3
- ITSKGMKPRYFWAL-UHFFFAOYSA-N 3-amino-6-thiophen-2-yl-n'-[3-(trifluoromethyl)phenyl]thieno[2,3-b]pyridine-2-carboximidamide Chemical compound C=1C=C2C(N)=C(C(=N)NC=3C=C(C=CC=3)C(F)(F)F)SC2=NC=1C1=CC=CS1 ITSKGMKPRYFWAL-UHFFFAOYSA-N 0.000 claims 3
- RJFUSXJFOTURBD-UHFFFAOYSA-N 3-amino-n-(2-bromophenyl)-6-(4-chlorophenyl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=1C=C2C(N)=C(C(=O)NC=3C(=CC=CC=3)Br)SC2=NC=1C1=CC=C(Cl)C=C1 RJFUSXJFOTURBD-UHFFFAOYSA-N 0.000 claims 3
- HCNPMXXHNSGZIL-UHFFFAOYSA-N 3-amino-n-(3-chlorophenyl)-6-(4-chlorophenyl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=1C=C2C(N)=C(C(=O)NC=3C=C(Cl)C=CC=3)SC2=NC=1C1=CC=C(Cl)C=C1 HCNPMXXHNSGZIL-UHFFFAOYSA-N 0.000 claims 3
- WCKRWUUQCCSAKL-UHFFFAOYSA-N 3-amino-n-(4-bromophenyl)-5-cyano-4-(furan-2-yl)-6-oxo-7h-thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=12C(N)=C(C(=O)NC=3C=CC(Br)=CC=3)SC2=NC(O)=C(C#N)C=1C1=CC=CO1 WCKRWUUQCCSAKL-UHFFFAOYSA-N 0.000 claims 3
- QMMAZEFRMSTWIP-UHFFFAOYSA-N 3-amino-n-(4-bromophenyl)-6-(5-chloropyridin-2-yl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=1C=C2C(N)=C(C(=O)NC=3C=CC(Br)=CC=3)SC2=NC=1C1=CC=C(Cl)C=N1 QMMAZEFRMSTWIP-UHFFFAOYSA-N 0.000 claims 3
- OVOGJEBYVKQGFY-UHFFFAOYSA-N 3-amino-n-(5-bromopyridin-2-yl)-6-(4-chlorophenyl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=1C=C2C(N)=C(C(=O)NC=3N=CC(Br)=CC=3)SC2=NC=1C1=CC=C(Cl)C=C1 OVOGJEBYVKQGFY-UHFFFAOYSA-N 0.000 claims 3
- FCJMUXBPDODZNP-UHFFFAOYSA-N 3-amino-n-(6-bromopyridin-3-yl)-6-(4-chlorophenyl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=1C=C2C(N)=C(C(=O)NC=3C=NC(Br)=CC=3)SC2=NC=1C1=CC=C(Cl)C=C1 FCJMUXBPDODZNP-UHFFFAOYSA-N 0.000 claims 3
- KREZENHBZZEWKP-UHFFFAOYSA-N 3-amino-n-[2-(dimethylamino)ethyl]-6-thiophen-2-yl-n-[3-(trifluoromethyl)phenyl]thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=1C=CC(C(F)(F)F)=CC=1N(CCN(C)C)C(=O)C(=C(C1=CC=2)N)SC1=NC=2C1=CC=CS1 KREZENHBZZEWKP-UHFFFAOYSA-N 0.000 claims 3
- SXPPZGHBPQOEFB-UHFFFAOYSA-N 3-amino-n-methyl-6-thiophen-2-yl-n-[3-(trifluoromethyl)phenyl]thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=1C=CC(C(F)(F)F)=CC=1N(C)C(=O)C(=C(C1=CC=2)N)SC1=NC=2C1=CC=CS1 SXPPZGHBPQOEFB-UHFFFAOYSA-N 0.000 claims 3
- WKYDMXGSNDBXRD-UHFFFAOYSA-N 3-amino-n-pyridin-4-yl-6-thiophen-2-ylthieno[2,3-b]pyridine-2-carboxamide Chemical compound C=1C=C2C(N)=C(C(=O)NC=3C=CN=CC=3)SC2=NC=1C1=CC=CS1 WKYDMXGSNDBXRD-UHFFFAOYSA-N 0.000 claims 3
- WXAGGIBKSXTNED-UHFFFAOYSA-N 6-acetamido-3-amino-n-(4-bromophenyl)-5-cyano-4-(furan-2-yl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound NC=1C=2C(C=3OC=CC=3)=C(C#N)C(NC(=O)C)=NC=2SC=1C(=O)NC1=CC=C(Br)C=C1 WXAGGIBKSXTNED-UHFFFAOYSA-N 0.000 claims 3
- YWRIATFFDFUQCS-UHFFFAOYSA-N 6-amino-10-fluoro-N-(5-phenyl-1,3,4-thiadiazol-2-yl)-4-thia-2-azatricyclo[7.5.0.03,7]tetradeca-1(9),2,5,7-tetraene-5-carboxamide Chemical compound S1C2=NC=3CCCCC(F)C=3C=C2C(N)=C1C(=O)NC(S1)=NN=C1C1=CC=CC=C1 YWRIATFFDFUQCS-UHFFFAOYSA-N 0.000 claims 3
- SKIOPINUHKJQNC-UHFFFAOYSA-N 6-amino-N-butyl-4-thia-2-azatricyclo[7.5.0.03,7]tetradeca-1,3(7),5,8-tetraene-5-carboxamide Chemical compound C1CCCCC2=C1N=C1SC(C(=O)NCCCC)=C(N)C1=C2 SKIOPINUHKJQNC-UHFFFAOYSA-N 0.000 claims 3
- JECJMCIQCXXWFM-UHFFFAOYSA-N 6-amino-N-cyclohexyl-4-thia-2-azatricyclo[7.5.0.03,7]tetradeca-1,3(7),5,8-tetraene-5-carboxamide Chemical compound S1C2=NC=3CCCCCC=3C=C2C(N)=C1C(=O)NC1CCCCC1 JECJMCIQCXXWFM-UHFFFAOYSA-N 0.000 claims 3
- XAKFZIQEDWJGJW-UHFFFAOYSA-N 6-amino-N-tert-butyl-4-thia-2-azatricyclo[7.5.0.03,7]tetradeca-1,3(7),5,8-tetraene-5-carboxamide Chemical compound C1CCCCC2=C1N=C1SC(C(=O)NC(C)(C)C)=C(N)C1=C2 XAKFZIQEDWJGJW-UHFFFAOYSA-N 0.000 claims 3
- PDFMOOJJTZAUJW-UHFFFAOYSA-N 7-thiophen-2-yl-3-[3-(trifluoromethyl)phenyl]-1h-pyrido[2,3]thieno[2,4-b]pyrimidine-2,4-dione Chemical compound FC(F)(F)C1=CC=CC(N2C(C=3SC4=NC(=CC=C4C=3NC2=O)C=2SC=CC=2)=O)=C1 PDFMOOJJTZAUJW-UHFFFAOYSA-N 0.000 claims 3
- XKKXSBRHLNKTRI-UHFFFAOYSA-N 8-thiophen-2-yl-4-[3-(trifluoromethyl)phenyl]-1,3-dihydropyrido[2,3]thieno[2,4-d][1,4]diazepine-2,5-dione Chemical compound FC(F)(F)C1=CC=CC(N2C(C3=C(C4=CC=C(N=C4S3)C=3SC=CC=3)NC(=O)C2)=O)=C1 XKKXSBRHLNKTRI-UHFFFAOYSA-N 0.000 claims 3
- KNOXMIMQBHGUMQ-UHFFFAOYSA-N 3-amino-6-(1,3-benzodioxol-5-yl)-n-(2-bromo-4-methylphenyl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound BrC1=CC(C)=CC=C1NC(=O)C1=C(N)C2=CC=C(C=3C=C4OCOC4=CC=3)N=C2S1 KNOXMIMQBHGUMQ-UHFFFAOYSA-N 0.000 claims 2
- ZWOJTAQYIULECL-UHFFFAOYSA-N 3-amino-6-(3-methoxyphenyl)-n-(2-phenoxyphenyl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound COC1=CC=CC(C=2N=C3SC(=C(N)C3=CC=2)C(=O)NC=2C(=CC=CC=2)OC=2C=CC=CC=2)=C1 ZWOJTAQYIULECL-UHFFFAOYSA-N 0.000 claims 2
- SZOOGVKGJCCILZ-UHFFFAOYSA-N 3-amino-n-(2,3-dichlorophenyl)-6-thiophen-2-ylthieno[2,3-b]pyridine-2-carboxamide Chemical compound C=1C=C2C(N)=C(C(=O)NC=3C(=C(Cl)C=CC=3)Cl)SC2=NC=1C1=CC=CS1 SZOOGVKGJCCILZ-UHFFFAOYSA-N 0.000 claims 2
- MMXJAEHFWYZYJK-UHFFFAOYSA-N 3-amino-n-(2,5-dichlorophenyl)-6-thiophen-2-ylthieno[2,3-b]pyridine-2-carboxamide Chemical compound C=1C=C2C(N)=C(C(=O)NC=3C(=CC=C(Cl)C=3)Cl)SC2=NC=1C1=CC=CS1 MMXJAEHFWYZYJK-UHFFFAOYSA-N 0.000 claims 2
- BXDYNMJWHMRNSX-UHFFFAOYSA-N 3-amino-n-(4-bromophenyl)-6-(3-methoxyphenyl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound COC1=CC=CC(C=2N=C3SC(=C(N)C3=CC=2)C(=O)NC=2C=CC(Br)=CC=2)=C1 BXDYNMJWHMRNSX-UHFFFAOYSA-N 0.000 claims 2
- 241000710831 Flavivirus Species 0.000 abstract description 8
- 241000710842 Japanese encephalitis virus Species 0.000 abstract description 6
- 241000710771 Tick-borne encephalitis virus Species 0.000 abstract description 4
- 241000710886 West Nile virus Species 0.000 abstract description 4
- 241000710772 Yellow fever virus Species 0.000 abstract description 4
- 229940051021 yellow-fever virus Drugs 0.000 abstract description 4
- RXGHULSMJIVVTA-UHFFFAOYSA-N thieno[2,3-b]pyridine-2-carboxamide Chemical compound C1=CN=C2SC(C(=O)N)=CC2=C1 RXGHULSMJIVVTA-UHFFFAOYSA-N 0.000 description 219
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 160
- 230000015572 biosynthetic process Effects 0.000 description 153
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 153
- 238000003786 synthesis reaction Methods 0.000 description 151
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 134
- 150000003857 carboxamides Chemical class 0.000 description 107
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 100
- 239000000243 solution Substances 0.000 description 89
- 238000005160 1H NMR spectroscopy Methods 0.000 description 82
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 82
- 239000007787 solid Substances 0.000 description 82
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 80
- 238000004949 mass spectrometry Methods 0.000 description 74
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 68
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 57
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 56
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 50
- 239000011541 reaction mixture Substances 0.000 description 50
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 48
- 201000010099 disease Diseases 0.000 description 46
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 46
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 36
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 34
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 34
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
- 238000009472 formulation Methods 0.000 description 33
- 125000000623 heterocyclic group Chemical group 0.000 description 32
- 239000000543 intermediate Substances 0.000 description 32
- 239000004480 active ingredient Substances 0.000 description 29
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 27
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 25
- 125000004433 nitrogen atom Chemical group N* 0.000 description 24
- 235000019260 propionic acid Nutrition 0.000 description 24
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 23
- 150000001408 amides Chemical class 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 23
- 150000001412 amines Chemical class 0.000 description 22
- 229960000583 acetic acid Drugs 0.000 description 21
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 21
- 230000000694 effects Effects 0.000 description 21
- 238000010992 reflux Methods 0.000 description 20
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 20
- 241000700605 Viruses Species 0.000 description 19
- 239000003814 drug Substances 0.000 description 19
- GKTQKQTXHNUFSP-UHFFFAOYSA-N thieno[3,4-c]pyrrole-4,6-dione Chemical compound S1C=C2C(=O)NC(=O)C2=C1 GKTQKQTXHNUFSP-UHFFFAOYSA-N 0.000 description 19
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 17
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 17
- 239000004615 ingredient Substances 0.000 description 17
- 208000015181 infectious disease Diseases 0.000 description 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- 125000001544 thienyl group Chemical group 0.000 description 16
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 238000003556 assay Methods 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 14
- 125000005805 dimethoxy phenyl group Chemical group 0.000 description 14
- 125000001207 fluorophenyl group Chemical group 0.000 description 14
- LOAUVZALPPNFOQ-UHFFFAOYSA-N quinaldic acid Chemical compound C1=CC=CC2=NC(C(=O)O)=CC=C21 LOAUVZALPPNFOQ-UHFFFAOYSA-N 0.000 description 14
- 208000024891 symptom Diseases 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 238000010898 silica gel chromatography Methods 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 238000001914 filtration Methods 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 125000000547 substituted alkyl group Chemical group 0.000 description 12
- 125000003107 substituted aryl group Chemical group 0.000 description 12
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 11
- 201000009892 dengue shock syndrome Diseases 0.000 description 11
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 11
- 239000012044 organic layer Substances 0.000 description 11
- 239000000546 pharmaceutical excipient Substances 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 230000003612 virological effect Effects 0.000 description 11
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 10
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 10
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 229920002472 Starch Polymers 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 239000012267 brine Substances 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 239000002002 slurry Substances 0.000 description 10
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
- 235000019698 starch Nutrition 0.000 description 10
- 125000005017 substituted alkenyl group Chemical group 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- BHPYMZQTCPRLNR-UHFFFAOYSA-N 2-cyanoethanethioamide Chemical compound NC(=S)CC#N BHPYMZQTCPRLNR-UHFFFAOYSA-N 0.000 description 9
- IYHHRZBKXXKDDY-UHFFFAOYSA-N BI-605906 Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C(F)(F)CC)=CC=1N1CCC(S(C)(=O)=O)CC1 IYHHRZBKXXKDDY-UHFFFAOYSA-N 0.000 description 9
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 9
- 230000000120 cytopathologic effect Effects 0.000 description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
- 238000001990 intravenous administration Methods 0.000 description 9
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 239000008107 starch Substances 0.000 description 9
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 8
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 8
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 125000000068 chlorophenyl group Chemical group 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- 229960000329 ribavirin Drugs 0.000 description 8
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 125000003944 tolyl group Chemical group 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 235000015165 citric acid Nutrition 0.000 description 7
- 125000004188 dichlorophenyl group Chemical group 0.000 description 7
- 229910052740 iodine Inorganic materials 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 125000004426 substituted alkynyl group Chemical group 0.000 description 7
- FFQCXFHARJCTBK-CMDGGOBGSA-N tert-butyl (4e)-4-(hydroxymethylidene)-5-oxoazepane-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)\C(=C\O)CC1 FFQCXFHARJCTBK-CMDGGOBGSA-N 0.000 description 7
- GOQFKSVPTVBQTC-UHFFFAOYSA-N tert-butyl 3-cyano-2-sulfanylidene-5,7,8,9-tetrahydro-1h-pyrido[3,2-c]azepine-6-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC2=C1C=C(C#N)C(=S)N2 GOQFKSVPTVBQTC-UHFFFAOYSA-N 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 6
- 240000008042 Zea mays Species 0.000 description 6
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 6
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 235000005822 corn Nutrition 0.000 description 6
- 239000005457 ice water Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- AVQJKZHCFZESJO-CMDGGOBGSA-N tert-butyl (3e)-3-(hydroxymethylidene)-4-oxoazepane-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(=O)\C(=C\O)C1 AVQJKZHCFZESJO-CMDGGOBGSA-N 0.000 description 6
- VBJJLUNGLGYIKW-UHFFFAOYSA-N tert-butyl 3-cyano-2-sulfanylidene-5,6,8,9-tetrahydro-1h-pyrido[2,3-d]azepine-7-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC2=C1NC(=S)C(C#N)=C2 VBJJLUNGLGYIKW-UHFFFAOYSA-N 0.000 description 6
- 210000003501 vero cell Anatomy 0.000 description 6
- 230000029812 viral genome replication Effects 0.000 description 6
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 5
- DWKYFSGFRCVIKO-UHFFFAOYSA-N 3-amino-6,7,8,9-tetrahydro-5h-thieno[4,5]pyrido[2,4-a]azepine-2-carboxylic acid Chemical compound C1CNCCC2=C1N=C1SC(C(O)=O)=C(N)C1=C2 DWKYFSGFRCVIKO-UHFFFAOYSA-N 0.000 description 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 5
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 5
- AGCQBGSDLGORJV-UHFFFAOYSA-N benzo[h]fluoren-1-one Chemical compound C1=CC=C2C=C3C4=CC=CC(=O)C4=CC3=CC2=C1 AGCQBGSDLGORJV-UHFFFAOYSA-N 0.000 description 5
- 125000001246 bromo group Chemical group Br* 0.000 description 5
- UZBQIPPOMKBLAS-UHFFFAOYSA-N diethylazanide Chemical compound CC[N-]CC UZBQIPPOMKBLAS-UHFFFAOYSA-N 0.000 description 5
- 239000007903 gelatin capsule Substances 0.000 description 5
- 238000013537 high throughput screening Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 235000015320 potassium carbonate Nutrition 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 239000011593 sulfur Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000012730 sustained-release form Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- GZEJMYFXZMUAEC-UHFFFAOYSA-O thieno[2,3-b]pyridine-2-carboxamidine Chemical compound C1=CN=C2SC(C(=[NH2+])N)=CC2=C1 GZEJMYFXZMUAEC-UHFFFAOYSA-O 0.000 description 5
- JDWFURAFRCAVOH-UHFFFAOYSA-N thieno[2,3-b]pyridine-5-carboxylic acid Chemical compound OC(=O)C1=CN=C2SC=CC2=C1 JDWFURAFRCAVOH-UHFFFAOYSA-N 0.000 description 5
- 239000003039 volatile agent Substances 0.000 description 5
- LPCGQVZJMGBSSD-UHFFFAOYSA-N (4-methylphenyl) 4-aminobenzenesulfonate Chemical compound C1=CC(C)=CC=C1OS(=O)(=O)C1=CC=C(N)C=C1 LPCGQVZJMGBSSD-UHFFFAOYSA-N 0.000 description 4
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 4
- OZZMWXQJCJUCEJ-UHFFFAOYSA-N 1,6-naphthyridine-2-carboxylic acid Chemical compound C1=NC=CC2=NC(C(=O)O)=CC=C21 OZZMWXQJCJUCEJ-UHFFFAOYSA-N 0.000 description 4
- SOWCVDMRPMZWHX-UHFFFAOYSA-N 1h-pyrido[2,3]thieno[2,4-b]pyrimidine-2,4-dione Chemical compound C12=CC=CN=C2SC2=C1NC(=O)NC2=O SOWCVDMRPMZWHX-UHFFFAOYSA-N 0.000 description 4
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 4
- DCAZINFOTIWSET-UHFFFAOYSA-N 3-(dimethylaminomethylidene)-1-methylpiperidin-4-one Chemical compound CN(C)C=C1CN(C)CCC1=O DCAZINFOTIWSET-UHFFFAOYSA-N 0.000 description 4
- VIUDTWATMPPKEL-UHFFFAOYSA-N 3-(trifluoromethyl)aniline Chemical compound NC1=CC=CC(C(F)(F)F)=C1 VIUDTWATMPPKEL-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 4
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- 241000255925 Diptera Species 0.000 description 4
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 4
- 108010081348 HRT1 protein Hairy Proteins 0.000 description 4
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 108010076039 Polyproteins Proteins 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 125000005605 benzo group Chemical group 0.000 description 4
- UPZQAWSYEJWASO-UHFFFAOYSA-N benzo[g]fluoren-8-one Chemical compound C1=CC=CC2=C3C4=CC=CC(=O)C4=CC3=CC=C21 UPZQAWSYEJWASO-UHFFFAOYSA-N 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000013058 crude material Substances 0.000 description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 description 4
- 125000000000 cycloalkoxy group Chemical group 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 150000004702 methyl esters Chemical class 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- LCEDQNDDFOCWGG-UHFFFAOYSA-N morpholine-4-carbaldehyde Chemical compound O=CN1CCOCC1 LCEDQNDDFOCWGG-UHFFFAOYSA-N 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- RAIYODFGMLZUDF-UHFFFAOYSA-N piperidin-1-ium;acetate Chemical compound CC([O-])=O.C1CC[NH2+]CC1 RAIYODFGMLZUDF-UHFFFAOYSA-N 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 125000005338 substituted cycloalkoxy group Chemical group 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 125000004001 thioalkyl group Chemical class 0.000 description 4
- 125000005000 thioaryl group Chemical group 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- TZYZKGVRPFWDGB-UHFFFAOYSA-N (4-methylphenyl) 4-[[3-amino-6-(4-chlorophenyl)thieno[2,3-b]pyridine-2-carbonyl]amino]benzenesulfonate Chemical compound C1=CC(C)=CC=C1OS(=O)(=O)C(C=C1)=CC=C1NC(=O)C1=C(N)C2=CC=C(C=3C=CC(Cl)=CC=3)N=C2S1 TZYZKGVRPFWDGB-UHFFFAOYSA-N 0.000 description 3
- ISROHQMFALHBEW-UHFFFAOYSA-N (4-methylphenyl) 4-nitrobenzenesulfonate Chemical compound C1=CC(C)=CC=C1OS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1 ISROHQMFALHBEW-UHFFFAOYSA-N 0.000 description 3
- QXTRPGAMVIONMK-UHFFFAOYSA-N 2-amino-5-ethyl-1,3,4-thiadiazole Chemical compound CCC1=NN=C(N)S1 QXTRPGAMVIONMK-UHFFFAOYSA-N 0.000 description 3
- FDPCSKPUJUALLE-UHFFFAOYSA-N 2-bromo-n-(4-bromophenyl)acetamide Chemical compound BrCC(=O)NC1=CC=C(Br)C=C1 FDPCSKPUJUALLE-UHFFFAOYSA-N 0.000 description 3
- JUIKUQOUMZUFQT-UHFFFAOYSA-N 2-bromoacetamide Chemical compound NC(=O)CBr JUIKUQOUMZUFQT-UHFFFAOYSA-N 0.000 description 3
- XXUNIGZDNWWYED-UHFFFAOYSA-N 2-methylbenzamide Chemical compound CC1=CC=CC=C1C(N)=O XXUNIGZDNWWYED-UHFFFAOYSA-N 0.000 description 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 3
- HMKMFICAAYAEOL-UHFFFAOYSA-N 3-amino-6,7,8,9-tetrahydro-5h-thieno[4,5]pyrido[2,4-a]azepine-2-carboxylic acid Chemical compound C1CCNCC2=C1N=C1SC(C(O)=O)=C(N)C1=C2 HMKMFICAAYAEOL-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 3
- 101150041968 CDC13 gene Proteins 0.000 description 3
- 241000710815 Dengue virus 2 Species 0.000 description 3
- 101100168634 Dictyostelium discoideum crnkl1 gene Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 101100168637 Rattus norvegicus Crnkl1 gene Proteins 0.000 description 3
- 101710172711 Structural protein Proteins 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- JPYQFYIEOUVJDU-UHFFFAOYSA-N beclamide Chemical compound ClCCC(=O)NCC1=CC=CC=C1 JPYQFYIEOUVJDU-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 3
- 125000004212 difluorophenyl group Chemical group 0.000 description 3
- DMBHHRLKUKUOEG-UHFFFAOYSA-N diphenylamine Chemical compound C=1C=CC=CC=1NC1=CC=CC=C1 DMBHHRLKUKUOEG-UHFFFAOYSA-N 0.000 description 3
- AAGQIGRNWCOJNQ-UHFFFAOYSA-N ethyl 5-cyano-6-sulfanylidene-1h-pyridine-3-carboxylate Chemical compound CCOC(=O)C1=CN=C(S)C(C#N)=C1 AAGQIGRNWCOJNQ-UHFFFAOYSA-N 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- NWPWGNPPZVZAKO-UHFFFAOYSA-N fluoren-1-one Chemical compound C1=CC=C2C3=CC=CC(=O)C3=CC2=C1 NWPWGNPPZVZAKO-UHFFFAOYSA-N 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- AICRIRMUNFSCED-UHFFFAOYSA-N n',n'-dimethyl-n-[3-(trifluoromethyl)phenyl]ethane-1,2-diamine Chemical compound CN(C)CCNC1=CC=CC(C(F)(F)F)=C1 AICRIRMUNFSCED-UHFFFAOYSA-N 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- XUWVIABDWDTJRZ-UHFFFAOYSA-N propan-2-ylazanide Chemical compound CC(C)[NH-] XUWVIABDWDTJRZ-UHFFFAOYSA-N 0.000 description 3
- 235000019833 protease Nutrition 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 3
- DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical compound CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 description 3
- 125000001680 trimethoxyphenyl group Chemical group 0.000 description 3
- 238000001665 trituration Methods 0.000 description 3
- VJLYHTOSFSGXGH-CQSZACIVSA-N (2R)-1-[3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxybenzoyl]pyrrolidine-2-carboxylic acid Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)N2[C@H](CCC2)C(=O)O)C=CC=1 VJLYHTOSFSGXGH-CQSZACIVSA-N 0.000 description 2
- RZNHMBDYRPYRAU-UHFFFAOYSA-N (4-methylphenyl) 4-[(2-bromoacetyl)amino]benzenesulfonate Chemical compound C1=CC(C)=CC=C1OS(=O)(=O)C1=CC=C(NC(=O)CBr)C=C1 RZNHMBDYRPYRAU-UHFFFAOYSA-N 0.000 description 2
- YKYIFUROKBDHCY-ONEGZZNKSA-N (e)-4-ethoxy-1,1,1-trifluorobut-3-en-2-one Chemical compound CCO\C=C\C(=O)C(F)(F)F YKYIFUROKBDHCY-ONEGZZNKSA-N 0.000 description 2
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 description 2
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 2
- GDPHNAZHHDEGFH-UHFFFAOYSA-N 1-[carbamimidoyl-(diaminomethylideneamino)sulfamoyl]-1-(diaminomethylideneamino)guanidine Chemical compound N(C(=N)N)N(C(=N)N)S(=O)(=O)N(C(=N)N)NC(=N)N GDPHNAZHHDEGFH-UHFFFAOYSA-N 0.000 description 2
- RUFPHBVGCFYCNW-UHFFFAOYSA-N 1-naphthylamine Chemical compound C1=CC=C2C(N)=CC=CC2=C1 RUFPHBVGCFYCNW-UHFFFAOYSA-N 0.000 description 2
- NOGFHTGYPKWWRX-UHFFFAOYSA-N 2,2,6,6-tetramethyloxan-4-one Chemical compound CC1(C)CC(=O)CC(C)(C)O1 NOGFHTGYPKWWRX-UHFFFAOYSA-N 0.000 description 2
- JULIBQBCWYYRTF-UHFFFAOYSA-N 2-(dimethylamino)-n-[3-(trifluoromethyl)phenyl]acetamide Chemical compound CN(C)CC(=O)NC1=CC=CC(C(F)(F)F)=C1 JULIBQBCWYYRTF-UHFFFAOYSA-N 0.000 description 2
- RCIZREZAMRROJQ-UHFFFAOYSA-N 2-(dimethylaminomethylidene)cycloheptane-1,3-dione Chemical compound CN(C)C=C1C(=O)CCCCC1=O RCIZREZAMRROJQ-UHFFFAOYSA-N 0.000 description 2
- NEKQNBBSVZDVFI-UHFFFAOYSA-N 2-(hydroxymethylidene)cycloheptan-1-one Chemical compound OC=C1CCCCCC1=O NEKQNBBSVZDVFI-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 2
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 2
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical compound C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 description 2
- VACYQQHEYITLDL-UHFFFAOYSA-N 2-bromo-n-[2-(dimethylamino)ethyl]-n-[3-(trifluoromethyl)phenyl]acetamide Chemical compound CN(C)CCN(C(=O)CBr)C1=CC=CC(C(F)(F)F)=C1 VACYQQHEYITLDL-UHFFFAOYSA-N 0.000 description 2
- OSKNAKFZYROIOL-UHFFFAOYSA-N 2-bromo-n-[3-(trifluoromethyl)phenyl]acetamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)CBr)=C1 OSKNAKFZYROIOL-UHFFFAOYSA-N 0.000 description 2
- JZNZPBRXKICNSM-UHFFFAOYSA-N 2-chloro-n'-[3-(trifluoromethyl)phenyl]ethanimidamide Chemical compound FC(F)(F)C1=CC=CC(NC(=N)CCl)=C1 JZNZPBRXKICNSM-UHFFFAOYSA-N 0.000 description 2
- AAMFDEPASMQJEF-UHFFFAOYSA-N 2-chloro-n-methyl-n-[3-(trifluoromethyl)phenyl]acetamide Chemical compound ClCC(=O)N(C)C1=CC=CC(C(F)(F)F)=C1 AAMFDEPASMQJEF-UHFFFAOYSA-N 0.000 description 2
- IEEHKTFVUIVORU-UHFFFAOYSA-N 2-methylpropanedioyl dichloride Chemical compound ClC(=O)C(C)C(Cl)=O IEEHKTFVUIVORU-UHFFFAOYSA-N 0.000 description 2
- JBIJLHTVPXGSAM-UHFFFAOYSA-N 2-naphthylamine Chemical compound C1=CC=CC2=CC(N)=CC=C21 JBIJLHTVPXGSAM-UHFFFAOYSA-N 0.000 description 2
- NCHMJHFUGUCVFT-UHFFFAOYSA-N 3-(dimethylamino)-1-(2,4-dimethyl-1,3-thiazol-5-yl)prop-2-en-1-one Chemical compound CN(C)C=CC(=O)C=1SC(C)=NC=1C NCHMJHFUGUCVFT-UHFFFAOYSA-N 0.000 description 2
- NXYSVZGMDFMOJJ-UHFFFAOYSA-N 3-(dimethylamino)-1-thiophen-2-ylprop-2-en-1-one Chemical compound CN(C)C=CC(=O)C1=CC=CS1 NXYSVZGMDFMOJJ-UHFFFAOYSA-N 0.000 description 2
- VTNULXUEOJMRKZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2H-tetrazol-5-ylmethyl)benzamide Chemical compound N=1NN=NC=1CNC(C1=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)=O VTNULXUEOJMRKZ-UHFFFAOYSA-N 0.000 description 2
- DUIJLHWEIXOLBQ-UHFFFAOYSA-N 3-amino-6,7,8,9-tetrahydro-5h-cyclohepta[b]-thieno[3,2-e]pyridine-2-carboxylic acid Chemical compound C1CCCCC2=C1N=C1SC(C(O)=O)=C(N)C1=C2 DUIJLHWEIXOLBQ-UHFFFAOYSA-N 0.000 description 2
- LCKLLBKKFAFFKN-UHFFFAOYSA-N 3-sulfanylpyridine-2-carbonitrile Chemical compound SC1=CC=CN=C1C#N LCKLLBKKFAFFKN-UHFFFAOYSA-N 0.000 description 2
- JVQYLXTVOCNCGC-UHFFFAOYSA-N 5-oxo-2-sulfanylidene-6,7,8,9-tetrahydro-1h-cyclohepta[b]pyridine-3-carbonitrile Chemical compound O=C1CCCCC2=C1C=C(C#N)C(=S)N2 JVQYLXTVOCNCGC-UHFFFAOYSA-N 0.000 description 2
- UHZHEOAEJRHUBW-UHFFFAOYSA-N 5-phenyl-1,3,4-thiadiazol-2-amine Chemical compound S1C(N)=NN=C1C1=CC=CC=C1 UHZHEOAEJRHUBW-UHFFFAOYSA-N 0.000 description 2
- QSBVUVPCUPRNNT-UHFFFAOYSA-N 8-oxabicyclo[5.1.0]octan-6-one Chemical compound O=C1CCCCC2OC12 QSBVUVPCUPRNNT-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- 101710204837 Envelope small membrane protein Proteins 0.000 description 2
- 241000710781 Flaviviridae Species 0.000 description 2
- 206010054261 Flavivirus infection Diseases 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 201000005807 Japanese encephalitis Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 102100020870 La-related protein 6 Human genes 0.000 description 2
- 108050008265 La-related protein 6 Proteins 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- 101710145006 Lysis protein Proteins 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 201000005805 Murray valley encephalitis Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical compound OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 206010041896 St. Louis Encephalitis Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 208000003152 Yellow Fever Diseases 0.000 description 2
- ZUSWDTWYONAOPH-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine;hydrochloride Chemical group [Cl-].[NH3+]NC1=CC=CC=C1C(F)(F)F ZUSWDTWYONAOPH-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 125000004181 carboxyalkyl group Chemical group 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000004696 coordination complex Chemical class 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- DBOVMTXPZWVYAQ-UHFFFAOYSA-N cycloheptane-1,3-dione Chemical compound O=C1CCCCC(=O)C1 DBOVMTXPZWVYAQ-UHFFFAOYSA-N 0.000 description 2
- HWDVTQAXQJQROO-UHFFFAOYSA-N cyclopropylazanide Chemical compound [NH-]C1CC1 HWDVTQAXQJQROO-UHFFFAOYSA-N 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 239000008387 emulsifying waxe Substances 0.000 description 2
- 239000012055 enteric layer Substances 0.000 description 2
- MWOUIHHHTGARFQ-UHFFFAOYSA-N ethyl 2-cyano-3-(furan-2-yl)prop-2-enoate Chemical compound CCOC(=O)C(C#N)=CC1=CC=CO1 MWOUIHHHTGARFQ-UHFFFAOYSA-N 0.000 description 2
- UMXNYWKLHWGZAN-UHFFFAOYSA-N ethyl 3-[3-(trifluoromethyl)anilino]propanoate Chemical compound CCOC(=O)CCNC1=CC=CC(C(F)(F)F)=C1 UMXNYWKLHWGZAN-UHFFFAOYSA-N 0.000 description 2
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 2
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003978 infusion fluid Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 235000016337 monopotassium tartrate Nutrition 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- WYURNTSHIVDZCO-SVYQBANQSA-N oxolane-d8 Chemical compound [2H]C1([2H])OC([2H])([2H])C([2H])([2H])C1([2H])[2H] WYURNTSHIVDZCO-SVYQBANQSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- KYKNRZGSIGMXFH-ZVGUSBNCSA-M potassium bitartrate Chemical compound [K+].OC(=O)[C@H](O)[C@@H](O)C([O-])=O KYKNRZGSIGMXFH-ZVGUSBNCSA-M 0.000 description 2
- 229940086065 potassium hydrogentartrate Drugs 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- NKAAEMMYHLFEFN-ZVGUSBNCSA-M sodium;(2r,3r)-2,3,4-trihydroxy-4-oxobutanoate Chemical compound [Na+].OC(=O)[C@H](O)[C@@H](O)C([O-])=O NKAAEMMYHLFEFN-ZVGUSBNCSA-M 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 125000005415 substituted alkoxy group Chemical group 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- HSDLVQWWEHCPHW-UHFFFAOYSA-N tert-butyl 2-[3-(trifluoromethyl)anilino]acetate Chemical compound CC(C)(C)OC(=O)CNC1=CC=CC(C(F)(F)F)=C1 HSDLVQWWEHCPHW-UHFFFAOYSA-N 0.000 description 2
- PMLBUVZPRKXMOX-UHFFFAOYSA-N tert-butyl 4-oxoazepane-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(=O)CC1 PMLBUVZPRKXMOX-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- XGCSHAYMNOFFNA-UHFFFAOYSA-N thieno[2,3-b]pyridine-2-carboxylic acid Chemical compound C1=CN=C2SC(C(=O)O)=CC2=C1 XGCSHAYMNOFFNA-UHFFFAOYSA-N 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- KDDNKZCVYQDGKE-UHFFFAOYSA-N (2-chlorophenyl)methanamine Chemical compound NCC1=CC=CC=C1Cl KDDNKZCVYQDGKE-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
- ZXAQFYZQHPGMMN-BZSJEYESSA-N (3R)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylcyclohexane-1-carboxamide Chemical compound C1C[C@H](CC(C1)C(=O)NC2=CC=CC=C2)OC3=CC(=CC(=N3)C(F)(F)F)CN ZXAQFYZQHPGMMN-BZSJEYESSA-N 0.000 description 1
- IIFVWLUQBAIPMJ-UHFFFAOYSA-N (4-fluorophenyl)methanamine Chemical compound NCC1=CC=C(F)C=C1 IIFVWLUQBAIPMJ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- YOTIBQOCCYWJMZ-UHFFFAOYSA-N 1,2,5-thiadiazole 1,1-dioxide Chemical class O=S1(=O)N=CC=N1 YOTIBQOCCYWJMZ-UHFFFAOYSA-N 0.000 description 1
- QUKGLNCXGVWCJX-UHFFFAOYSA-N 1,3,4-thiadiazol-2-amine Chemical compound NC1=NN=CS1 QUKGLNCXGVWCJX-UHFFFAOYSA-N 0.000 description 1
- FEWLNYSYJNLUOO-UHFFFAOYSA-N 1-Piperidinecarboxaldehyde Chemical compound O=CN1CCCCC1 FEWLNYSYJNLUOO-UHFFFAOYSA-N 0.000 description 1
- FODBVCSYJKNBLO-UHFFFAOYSA-N 2,3-dimethoxybenzoic acid Chemical compound COC1=CC=CC(C(O)=O)=C1OC FODBVCSYJKNBLO-UHFFFAOYSA-N 0.000 description 1
- VVAKEQGKZNKUSU-UHFFFAOYSA-N 2,3-dimethylaniline Chemical compound CC1=CC=CC(N)=C1C VVAKEQGKZNKUSU-UHFFFAOYSA-N 0.000 description 1
- KWVPRPSXBZNOHS-UHFFFAOYSA-N 2,4,6-Trimethylaniline Chemical compound CC1=CC(C)=C(N)C(C)=C1 KWVPRPSXBZNOHS-UHFFFAOYSA-N 0.000 description 1
- CZZZABOKJQXEBO-UHFFFAOYSA-N 2,4-dimethylaniline Chemical compound CC1=CC=C(N)C(C)=C1 CZZZABOKJQXEBO-UHFFFAOYSA-N 0.000 description 1
- JYWKEVKEKOTYEX-UHFFFAOYSA-N 2,6-dibromo-4-chloroiminocyclohexa-2,5-dien-1-one Chemical compound ClN=C1C=C(Br)C(=O)C(Br)=C1 JYWKEVKEKOTYEX-UHFFFAOYSA-N 0.000 description 1
- VTYRPALGSNDUQQ-UHFFFAOYSA-N 2-(dimethylamino)acetyl chloride Chemical compound CN(C)CC(Cl)=O VTYRPALGSNDUQQ-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- UHGULLIUJBCTEF-UHFFFAOYSA-N 2-aminobenzothiazole Chemical compound C1=CC=C2SC(N)=NC2=C1 UHGULLIUJBCTEF-UHFFFAOYSA-N 0.000 description 1
- MLPVBIWIRCKMJV-UHFFFAOYSA-N 2-ethylaniline Chemical compound CCC1=CC=CC=C1N MLPVBIWIRCKMJV-UHFFFAOYSA-N 0.000 description 1
- FTZQXOJYPFINKJ-UHFFFAOYSA-N 2-fluoroaniline Chemical compound NC1=CC=CC=C1F FTZQXOJYPFINKJ-UHFFFAOYSA-N 0.000 description 1
- AUVALWUPUHHNQV-UHFFFAOYSA-N 2-hydroxy-3-propylbenzoic acid Chemical class CCCC1=CC=CC(C(O)=O)=C1O AUVALWUPUHHNQV-UHFFFAOYSA-N 0.000 description 1
- JDTUPLBMGDDPJS-UHFFFAOYSA-N 2-methoxy-2-phenylethanol Chemical compound COC(CO)C1=CC=CC=C1 JDTUPLBMGDDPJS-UHFFFAOYSA-N 0.000 description 1
- ITXHYKBXKRUJNO-UHFFFAOYSA-N 2-methylthieno[2,3-b]pyridine Chemical compound C1=CN=C2SC(C)=CC2=C1 ITXHYKBXKRUJNO-UHFFFAOYSA-N 0.000 description 1
- YBZUSSJUKKQSKW-UHFFFAOYSA-N 3-(trifluoromethyl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C1=CC=C2C(C(F)(F)F)=C(C(=O)N)SC2=N1 YBZUSSJUKKQSKW-UHFFFAOYSA-N 0.000 description 1
- UPFWUWSKRSHNOG-UHFFFAOYSA-N 3-(trifluoromethyl)thieno[2,3-b]pyridine-2-carboxylic acid Chemical compound FC(F)(F)C1=C(SC2=NC=CC=C21)C(=O)O UPFWUWSKRSHNOG-UHFFFAOYSA-N 0.000 description 1
- LIDBMZYKSAXTQG-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2-sulfamoylethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCCS(N)(=O)=O)C=CC=1 LIDBMZYKSAXTQG-UHFFFAOYSA-N 0.000 description 1
- ZMCQQCBOZIGNRV-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[2-(1,2,4-triazol-1-yl)ethyl]benzamide Chemical compound NCC1=CC(OC2=CC=CC(=C2)C(=O)NCCN2C=NC=N2)=NC(=C1)C(F)(F)F ZMCQQCBOZIGNRV-UHFFFAOYSA-N 0.000 description 1
- VVPGEFWZAXBZHR-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]sulfanyl-N-phenylbenzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)SC=1C=C(C(=O)NC2=CC=CC=C2)C=CC=1 VVPGEFWZAXBZHR-UHFFFAOYSA-N 0.000 description 1
- DHDJIMYHPMEMTR-UHFFFAOYSA-N 3-amino-4,6-dimethylthieno[2,3-b]pyridine-2-carboxylic acid Chemical compound CC1=CC(C)=C2C(N)=C(C(O)=O)SC2=N1 DHDJIMYHPMEMTR-UHFFFAOYSA-N 0.000 description 1
- CZQKVWVHONXLGD-UHFFFAOYSA-N 3-amino-6-(2-methylpropyl)thieno[2,3-b]pyridine-2-carboxylic acid Chemical compound CC(C)CC1=CC=C2C(N)=C(C(O)=O)SC2=N1 CZQKVWVHONXLGD-UHFFFAOYSA-N 0.000 description 1
- IJXNTEUARVESGR-UHFFFAOYSA-N 3-amino-6-(4-methylphenyl)-n-phenylthieno[2,3-b]pyridine-2-carboxamide Chemical compound C1=CC(C)=CC=C1C1=CC=C(C(N)=C(S2)C(=O)NC=3C=CC=CC=3)C2=N1 IJXNTEUARVESGR-UHFFFAOYSA-N 0.000 description 1
- XLHOLCROQFJXGJ-UHFFFAOYSA-N 3-amino-n-(2-bromo-4-methylphenyl)-6-(3-methoxyphenyl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound COC1=CC=CC(C=2N=C3SC(=C(N)C3=CC=2)C(=O)NC=2C(=CC(C)=CC=2)Br)=C1 XLHOLCROQFJXGJ-UHFFFAOYSA-N 0.000 description 1
- OQJLHHRXXWKEDT-UHFFFAOYSA-N 3-amino-n-(2-chloro-4-fluorophenyl)-6-(3-methoxyphenyl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound COC1=CC=CC(C=2N=C3SC(=C(N)C3=CC=2)C(=O)NC=2C(=CC(F)=CC=2)Cl)=C1 OQJLHHRXXWKEDT-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- BNTNWQPIBPBJOO-UHFFFAOYSA-N 3-chloro-2,4-difluoroaniline Chemical compound NC1=CC=C(F)C(Cl)=C1F BNTNWQPIBPBJOO-UHFFFAOYSA-N 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- FNXYWHTZDAVRTB-UHFFFAOYSA-N 3-methyl-1,2-oxazol-5-amine Chemical compound CC=1C=C(N)ON=1 FNXYWHTZDAVRTB-UHFFFAOYSA-N 0.000 description 1
- JJYPMNFTHPTTDI-UHFFFAOYSA-N 3-methylaniline Chemical compound CC1=CC=CC(N)=C1 JJYPMNFTHPTTDI-UHFFFAOYSA-N 0.000 description 1
- KEYBKLFIHAFLOH-UHFFFAOYSA-N 3-phenylthieno[2,3-b]pyridine-2-carboxamide Chemical compound NC(=O)C=1SC2=NC=CC=C2C=1C1=CC=CC=C1 KEYBKLFIHAFLOH-UHFFFAOYSA-N 0.000 description 1
- YIJHSHSOQOKYFM-UHFFFAOYSA-N 3-thiophen-2-ylthieno[2,3-b]pyridine-2-carboxamide Chemical compound NC(=O)C=1SC2=NC=CC=C2C=1C1=CC=CS1 YIJHSHSOQOKYFM-UHFFFAOYSA-N 0.000 description 1
- QEIVWSRXBYOTAZ-UHFFFAOYSA-N 4-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylpiperidine-1-carboxamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC1CCN(CC1)C(=O)NC1=CC=CC=C1 QEIVWSRXBYOTAZ-UHFFFAOYSA-N 0.000 description 1
- HOWFLZVASJDZRZ-UHFFFAOYSA-N 4-[[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxymethyl]-N-phenylpiperidine-1-carboxamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OCC1CCN(CC1)C(=O)NC1=CC=CC=C1 HOWFLZVASJDZRZ-UHFFFAOYSA-N 0.000 description 1
- XWQVQSXLXAXOPJ-QNGMFEMESA-N 4-[[[6-[5-chloro-2-[[4-[[(2r)-1-methoxypropan-2-yl]amino]cyclohexyl]amino]pyridin-4-yl]pyridin-2-yl]amino]methyl]oxane-4-carbonitrile Chemical compound C1CC(N[C@H](C)COC)CCC1NC1=CC(C=2N=C(NCC3(CCOCC3)C#N)C=CC=2)=C(Cl)C=N1 XWQVQSXLXAXOPJ-QNGMFEMESA-N 0.000 description 1
- YBAZINRZQSAIAY-UHFFFAOYSA-N 4-aminobenzonitrile Chemical compound NC1=CC=C(C#N)C=C1 YBAZINRZQSAIAY-UHFFFAOYSA-N 0.000 description 1
- WDFQBORIUYODSI-UHFFFAOYSA-N 4-bromoaniline Chemical compound NC1=CC=C(Br)C=C1 WDFQBORIUYODSI-UHFFFAOYSA-N 0.000 description 1
- QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 description 1
- AZRRZGIBBLWSSQ-UHFFFAOYSA-N 4-ethyl-7-phenyl-3,5-diazabicyclo[2.2.2]octane-2,6-dione Chemical compound N1C(=O)C2C(=O)NC1(CC)CC2C1=CC=CC=C1 AZRRZGIBBLWSSQ-UHFFFAOYSA-N 0.000 description 1
- KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
- OUQMXTJYCAJLGO-UHFFFAOYSA-N 4-methyl-1,3-thiazol-2-amine Chemical compound CC1=CSC(N)=N1 OUQMXTJYCAJLGO-UHFFFAOYSA-N 0.000 description 1
- WRDWWAVNELMWAM-UHFFFAOYSA-N 4-tert-butylaniline Chemical compound CC(C)(C)C1=CC=C(N)C=C1 WRDWWAVNELMWAM-UHFFFAOYSA-N 0.000 description 1
- QRCGFTXRXYMJOS-UHFFFAOYSA-N 4h-1,4-benzoxazin-3-one Chemical compound C1=CC=C2NC(=O)COC2=C1 QRCGFTXRXYMJOS-UHFFFAOYSA-N 0.000 description 1
- WREVVZMUNPAPOV-UHFFFAOYSA-N 8-aminoquinoline Chemical compound C1=CN=C2C(N)=CC=CC2=C1 WREVVZMUNPAPOV-UHFFFAOYSA-N 0.000 description 1
- MAAJVFRSBXDABQ-UHFFFAOYSA-N 9,14,16-triazatetracyclo[8.7.0.02,7.012,17]heptadeca-1,4,6,8,10,12,14,16-octaen-3-one Chemical compound C1(C=CC=C2C=NC3=CC=4C=NC=NC4C3=C21)=O MAAJVFRSBXDABQ-UHFFFAOYSA-N 0.000 description 1
- DXIBRFHEZZOPFH-UHFFFAOYSA-N 9-(2-oxolanyl)-3H-purine-6-thione Chemical compound C1=NC=2C(=S)N=CNC=2N1C1CCCO1 DXIBRFHEZZOPFH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 241000256118 Aedes aegypti Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101100042610 Arabidopsis thaliana SIGB gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108700016947 Bos taurus structural-GP Proteins 0.000 description 1
- PQODYSZXAMQSAS-UHFFFAOYSA-N CC([S+]1C(C)=NC(C)=C1)=O Chemical compound CC([S+]1C(C)=NC(C)=C1)=O PQODYSZXAMQSAS-UHFFFAOYSA-N 0.000 description 1
- 101100494773 Caenorhabditis elegans ctl-2 gene Proteins 0.000 description 1
- 101100309570 Caenorhabditis elegans let-765 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- RENMDAKOXSCIGH-UHFFFAOYSA-N Chloroacetonitrile Chemical compound ClCC#N RENMDAKOXSCIGH-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102100035861 Cytosolic 5'-nucleotidase 1A Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108700003101 Dengue virus NS4B Proteins 0.000 description 1
- 241000710829 Dengue virus group Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 101100112369 Fasciola hepatica Cat-1 gene Proteins 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101000933374 Gallus gallus Brain-specific homeobox/POU domain protein 3 Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102100034535 Histone H3.1 Human genes 0.000 description 1
- 101000802744 Homo sapiens Cytosolic 5'-nucleotidase 1A Proteins 0.000 description 1
- 101001067844 Homo sapiens Histone H3.1 Proteins 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 206010021138 Hypovolaemic shock Diseases 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- YCDFQGIYFDVACM-UHFFFAOYSA-N N,N-dibutyl-1H-cyclopenta[a]naphthalene-2-carboxamide Chemical compound C(CCC)N(C(=O)C1=CC=2C(=C3C=CC=CC3=CC2)C1)CCCC YCDFQGIYFDVACM-UHFFFAOYSA-N 0.000 description 1
- DFPHFPQADBCOMZ-UHFFFAOYSA-N N-(4-methylphenyl)cyclohepta[f]indene-2-carboxamide Chemical compound C1=CC(C)=CC=C1NC(=O)C1=CC2=CC3=CC=CC=CC3=CC2=C1 DFPHFPQADBCOMZ-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- KQBCSLXQIDONHO-UHFFFAOYSA-N N-phenylcyclohepta[f]indene-2-carboxamide Chemical compound C=1C2=CC3=CC=CC=CC3=CC2=CC=1C(=O)NC1=CC=CC=C1 KQBCSLXQIDONHO-UHFFFAOYSA-N 0.000 description 1
- UQYYZDWUSQZMTP-UHFFFAOYSA-N NC(C(C=C1)(Br)Br)C=C1Br Chemical compound NC(C(C=C1)(Br)Br)C=C1Br UQYYZDWUSQZMTP-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 101100005271 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cat-1 gene Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 101800000508 Non-structural protein 5 Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 208000009341 RNA Virus Infections Diseases 0.000 description 1
- 206010037870 Rash morbilliform Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 241001591005 Siga Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000005485 Thrombocytosis Diseases 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- ICMGLRUYEQNHPF-UHFFFAOYSA-N Uraprene Chemical compound COC1=CC=CC=C1N1CCN(CCCNC=2N(C(=O)N(C)C(=O)C=2)C)CC1 ICMGLRUYEQNHPF-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 208000028227 Viral hemorrhagic fever Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- RWQJLIWMOBYOTI-AWEZNQCLSA-N [(3S)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxypiperidin-1-yl]-pyridin-3-ylmethanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)O[C@@H]1CN(CCC1)C(=O)C=1C=NC=CC=1 RWQJLIWMOBYOTI-AWEZNQCLSA-N 0.000 description 1
- YKKPYMXANSSQCA-UHFFFAOYSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-(3-pyrazol-1-ylazetidin-1-yl)methanone Chemical compound N1(N=CC=C1)C1CN(C1)C(=O)C1=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F YKKPYMXANSSQCA-UHFFFAOYSA-N 0.000 description 1
- JWSIZPAOIFLWKM-UHFFFAOYSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-[3-(dimethylamino)-4-hydroxypyrrolidin-1-yl]methanone Chemical compound CN(C)C1CN(CC1O)C(=O)c1cccc(Oc2cc(CN)cc(n2)C(F)(F)F)c1 JWSIZPAOIFLWKM-UHFFFAOYSA-N 0.000 description 1
- IQUWAPNUQVLWGG-GFCCVEGCSA-N [5-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxypyridin-3-yl]-[(3R)-3-aminopyrrolidin-1-yl]methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=NC=1)C(=O)N1C[C@@H](CC1)N IQUWAPNUQVLWGG-GFCCVEGCSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000005431 alkyl carboxamide group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000010945 base-catalyzed hydrolysis reactiony Methods 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QRZGKKJRSA-N beta-cellobiose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QRZGKKJRSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- KFCUPNHUPHDVJC-UHFFFAOYSA-N bromine azide Chemical compound BrN=[N+]=[N-] KFCUPNHUPHDVJC-UHFFFAOYSA-N 0.000 description 1
- 125000004799 bromophenyl group Chemical group 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- KMGBZBJJOKUPIA-UHFFFAOYSA-N butyl iodide Chemical compound CCCCI KMGBZBJJOKUPIA-UHFFFAOYSA-N 0.000 description 1
- MSZJEPVVQWJCIF-UHFFFAOYSA-N butylazanide Chemical compound CCCC[NH-] MSZJEPVVQWJCIF-UHFFFAOYSA-N 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000004289 cerebral ventricle Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- JYWJULGYGOLCGW-UHFFFAOYSA-N chloromethyl chloroformate Chemical compound ClCOC(Cl)=O JYWJULGYGOLCGW-UHFFFAOYSA-N 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 229940069078 citric acid / sodium citrate Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- WZCRDVTWUYLPTR-UHFFFAOYSA-N cyclohept-2-en-1-one Chemical compound O=C1CCCCC=C1 WZCRDVTWUYLPTR-UHFFFAOYSA-N 0.000 description 1
- PUBYKPQXQOSRSE-UHFFFAOYSA-N cyclohepta[f]benzimidazole-2-carboxylic acid Chemical compound N1=C(N=C2C=C3C(C=C12)=CC=CC=C3)C(=O)O PUBYKPQXQOSRSE-UHFFFAOYSA-N 0.000 description 1
- BOQLXDJIQVMNJT-UHFFFAOYSA-N cyclohepta[f]indene-2-carboxylic acid Chemical compound C1=CC=CC2=CC3=CC(C(=O)O)=CC3=CC2=C1 BOQLXDJIQVMNJT-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 229940023605 dengue virus vaccine Drugs 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 125000005432 dialkylcarboxamide group Chemical group 0.000 description 1
- 125000005266 diarylamine group Chemical group 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000006001 difluoroethyl group Chemical group 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical group C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- DFXMNICBESIPEZ-UHFFFAOYSA-N dimethoxy(phenyl)methanamine Chemical compound COC(N)(OC)C1=CC=CC=C1 DFXMNICBESIPEZ-UHFFFAOYSA-N 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- BFXLJWUGRPGMFU-UHFFFAOYSA-N dipropoxyphosphinothioyl n,n-diethylcarbamodithioate;sulfane Chemical compound S.CCCOP(=S)(OCCC)SC(=S)N(CC)CC BFXLJWUGRPGMFU-UHFFFAOYSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- MSJMDZAOKORVFC-UAIGNFCESA-L disodium maleate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C/C([O-])=O MSJMDZAOKORVFC-UAIGNFCESA-L 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- KGMAJUSPKMDFKI-UHFFFAOYSA-N ethyl 2,3,3a,4-tetrahydro-1-benzothiophene-3-carboxylate Chemical compound C(C)OC(=O)C1C2C(SC1)=CC=CC2 KGMAJUSPKMDFKI-UHFFFAOYSA-N 0.000 description 1
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 1
- FQTIYMRSUOADDK-UHFFFAOYSA-N ethyl 3-bromopropanoate Chemical compound CCOC(=O)CCBr FQTIYMRSUOADDK-UHFFFAOYSA-N 0.000 description 1
- CLMIRNDQXLEBHS-UHFFFAOYSA-N ethyl 7-amino-4-oxo-1h-1,8-naphthyridine-3-carboxylate Chemical compound NC1=CC=C2C(=O)C(C(=O)OCC)=CNC2=N1 CLMIRNDQXLEBHS-UHFFFAOYSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000012054 flavored emulsion Substances 0.000 description 1
- 235000020375 flavoured syrup Nutrition 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- DDRPCXLAQZKBJP-UHFFFAOYSA-N furfurylamine Chemical compound NCC1=CC=CO1 DDRPCXLAQZKBJP-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 238000012188 high-throughput screening assay Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 229940021223 hypertonic solution Drugs 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940087857 lupron Drugs 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000001115 mace Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- RDBBFJAPMNVENH-UHFFFAOYSA-N methyl 1h-pyrazolo[4,3-b]pyridine-5-carboxylate Chemical compound COC(=O)C1=CC=C2NN=CC2=N1 RDBBFJAPMNVENH-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- FOZCYSFGGSMPTO-UHFFFAOYSA-N n-(furan-2-ylmethyl)-3,4,6-trimethylthieno[2,3-b]pyridine-2-carboxamide Chemical compound S1C2=NC(C)=CC(C)=C2C(C)=C1C(=O)NCC1=CC=CO1 FOZCYSFGGSMPTO-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- SRTKIHVQZYXHHJ-UHFFFAOYSA-N n-methyl-3-(trifluoromethyl)aniline Chemical compound CNC1=CC=CC(C(F)(F)F)=C1 SRTKIHVQZYXHHJ-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940042443 other antivirals in atc Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical class [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- LVOICKNPHXSSQM-UHFFFAOYSA-N prop-2-en-1-one Chemical compound C=C[C]=O LVOICKNPHXSSQM-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical class [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 1
- LEIAZUKOBVWTEH-UHFFFAOYSA-N pyridine-2,5-dicarboxamide Chemical compound NC(=O)C1=CC=C(C(N)=O)N=C1 LEIAZUKOBVWTEH-UHFFFAOYSA-N 0.000 description 1
- WIRTYVGMQVIVDM-UHFFFAOYSA-N pyridine-3-carbonitrile Chemical compound N#CC1=C=NC=C[CH]1 WIRTYVGMQVIVDM-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- GYESAYHWISMZOK-UHFFFAOYSA-N quinolin-5-ol Chemical compound C1=CC=C2C(O)=CC=CC2=N1 GYESAYHWISMZOK-UHFFFAOYSA-N 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- MMJOCKKLRMRSEQ-AFCXAGJDSA-N ribavirin 5'-triphosphate Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 MMJOCKKLRMRSEQ-AFCXAGJDSA-N 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 101150117326 sigA gene Proteins 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- IZUPJOYPPLEPGM-UHFFFAOYSA-M sodium;hydron;phthalate Chemical compound [Na+].OC(=O)C1=CC=CC=C1C([O-])=O IZUPJOYPPLEPGM-UHFFFAOYSA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000012810 sudden onset of fever Diseases 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940066769 systemic antihistamines substituted alkylamines Drugs 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- KUYMVWXKHQSIAS-UHFFFAOYSA-N tert-butyl 2-chloroacetate Chemical compound CC(C)(C)OC(=O)CCl KUYMVWXKHQSIAS-UHFFFAOYSA-N 0.000 description 1
- TZRQZPMQUXEZMC-UHFFFAOYSA-N tert-butyl n-(2-bromoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCBr TZRQZPMQUXEZMC-UHFFFAOYSA-N 0.000 description 1
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 1
- FSEPCRFINOFJMC-UHFFFAOYSA-N thieno[2,3-b]quinoline-2-carboxylic acid Chemical compound C1=CC=C2N=C(SC(C(=O)O)=C3)C3=CC2=C1 FSEPCRFINOFJMC-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000008181 tonicity modifier Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 125000005259 triarylamine group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- NRTLTGGGUQIRRT-UHFFFAOYSA-N triethylazanium;bromide Chemical compound [Br-].CC[NH+](CC)CC NRTLTGGGUQIRRT-UHFFFAOYSA-N 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/708,224 | 2012-12-07 | ||
US13/708,224 US20130129677A1 (en) | 2009-02-27 | 2012-12-07 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections |
PCT/US2013/073449 WO2014089378A1 (en) | 2012-12-07 | 2013-12-06 | Thienopyridine derivatives for the treatment and prevention of dengue virus infections |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2893318A1 true CA2893318A1 (en) | 2014-06-12 |
Family
ID=50884015
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2893318A Abandoned CA2893318A1 (en) | 2012-12-07 | 2013-12-06 | Thienopyridine derivatives for the treatment and prevention of dengue virus infections |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2928470A4 (enrdf_load_stackoverflow) |
JP (1) | JP2016501883A (enrdf_load_stackoverflow) |
CA (1) | CA2893318A1 (enrdf_load_stackoverflow) |
WO (1) | WO2014089378A1 (enrdf_load_stackoverflow) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105418635A (zh) * | 2015-12-25 | 2016-03-23 | 上海应用技术学院 | 一种噻吩并吡啶类医药中间体的合成方法 |
CN105769866B (zh) * | 2016-03-31 | 2018-05-04 | 南通江海港建设工程有限公司 | 一种化合物在增加血小板浓度药物中的用途 |
CN105832734B (zh) * | 2016-03-31 | 2018-05-04 | 南通江海港建设工程有限公司 | 一种化合物在增加血小板浓度药物中的用途 |
JP7041877B2 (ja) * | 2016-06-14 | 2022-03-25 | 国立大学法人 東京大学 | チエノ[2,3-b]ピリジン誘導体およびキノリン誘導体ならびにそれらの使用 |
EP3704126A4 (en) | 2017-11-03 | 2020-12-09 | Université de Montréal | COMPOUNDS AND THEIR USE IN THE EXPANSION OF STEM CELLS AND / OR PROGENITOR CELLS |
JP7445609B2 (ja) * | 2018-06-06 | 2024-03-07 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Epac阻害剤としてのチエノ[2,3-b]ピリジン誘導体及びその医薬用途 |
WO2021035258A1 (en) * | 2019-08-21 | 2021-02-25 | The Scripps Research Institute | Bicyclic agonists of stimulator of interferon genes sting |
CN111072463A (zh) * | 2019-12-03 | 2020-04-28 | 辽宁凯莱英医药化学有限公司 | 一种4-乙氧基-1,1,1-三氟-3-丁烯-2-酮的连续化合成方法 |
WO2021108999A1 (zh) * | 2019-12-03 | 2021-06-10 | 辽宁凯莱英医药化学有限公司 | 一种4-乙氧基-1,1,1-三氟-3-丁烯-2-酮的连续化合成方法 |
WO2021250231A1 (en) * | 2020-06-12 | 2021-12-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Thienopyridine derivatives for use in the treatment of coronavirus infection |
WO2022094816A1 (en) * | 2020-11-04 | 2022-05-12 | Janssen Pharmaceuticals, Inc. | Solid formulation |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0785193A4 (en) * | 1994-09-22 | 2000-04-19 | Rational Drug Design Lab | ARYLTHIADIAZOLE DERIVATIVES AND ANTIVIRAL PRODUCTS CONTAINING THEM |
GB9717576D0 (en) * | 1997-08-19 | 1997-10-22 | Xenova Ltd | Pharmaceutical compounds |
US6608053B2 (en) * | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
US7202363B2 (en) * | 2003-07-24 | 2007-04-10 | Abbott Laboratories | Thienopyridine and furopyridine kinase inhibitors |
AR048669A1 (es) * | 2004-03-03 | 2006-05-17 | Syngenta Ltd | Derivados biciclicos de bisamida |
SE0403171D0 (sv) * | 2004-12-23 | 2004-12-23 | Astrazeneca Ab | New compounds |
JP2006298909A (ja) * | 2005-03-25 | 2006-11-02 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
JP2009537551A (ja) * | 2006-05-17 | 2009-10-29 | アメリカ合衆国 | ホルモン受容体を調節するためのピリミジン低分子量リガンド |
US20130129677A1 (en) * | 2009-02-27 | 2013-05-23 | Siga Technologies, Inc. | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections |
EP2400845B1 (en) * | 2009-02-27 | 2017-02-22 | Siga Technologies, Inc. | Thienopyridine derivatives for the treatment and prevention of dengue virus infections |
US8785499B2 (en) * | 2009-07-10 | 2014-07-22 | University Of Maryland, Baltimore | Targeting NAD biosynthesis in bacterial pathogens |
-
2013
- 2013-12-06 JP JP2015545858A patent/JP2016501883A/ja active Pending
- 2013-12-06 WO PCT/US2013/073449 patent/WO2014089378A1/en active Application Filing
- 2013-12-06 CA CA2893318A patent/CA2893318A1/en not_active Abandoned
- 2013-12-06 EP EP13859644.0A patent/EP2928470A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP2928470A4 (en) | 2015-12-16 |
WO2014089378A1 (en) | 2014-06-12 |
JP2016501883A (ja) | 2016-01-21 |
EP2928470A1 (en) | 2015-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2893318A1 (en) | Thienopyridine derivatives for the treatment and prevention of dengue virus infections | |
AU2010218152B2 (en) | Thienopyridine derivatives for the treatment and prevention of Dengue virus infections | |
JP4109271B2 (ja) | 置換されたアリールアシルチオ尿素および関連化合物;ウイルス複製のインヒビター | |
US20130129677A1 (en) | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | |
CN104507481B (zh) | 用于治疗、改善或预防病毒疾病的7‑氧代‑4,7‑二氢‑吡唑并[1,5‑a]嘧啶衍生物 | |
CA2850976C (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
AU2008256727A1 (en) | Antiviral drugs for treatment or prevention of dengue infection | |
CA2726985A1 (en) | Small molecule inhibitors for the treatment or prevention of dengue virus infection | |
CN104428301A (zh) | Nampt抑制剂 | |
AU2010266570A1 (en) | Treatment and prevention of Dengue virus infections | |
MX2011006514A (es) | Compuesto y metodo de uso. | |
AU2012322698A1 (en) | 8 - carbamoyl - 2 - (2,3- di substituted pyrid - 6 - yl) -1,2,3,4 -tetrahydroisoquinoline derivatives as apoptosis - inducing agents for the treatment of cancer and immune and autoimmune diseases | |
CN103347860A (zh) | Nampt抑制剂 | |
CN104271572A (zh) | 用作nampt抑制剂的噻唑羧酰胺衍生物 | |
DE102005028077A1 (de) | Alkinyl-substituierte Thiophene | |
JP2008526817A (ja) | 新規のピロロジヒドロイソキノリン | |
WO2010082044A1 (en) | Unsaturated bicyclic heterocyclic derivatives as smo antagonists | |
US20070259911A1 (en) | Novel Compounds and Use of Tetrahydropyridothiophenes | |
CN116261454A (zh) | 转录激活蛋白的咪唑并哌嗪抑制剂 | |
AU2015203873A1 (en) | Thienopyridine derivatives for the treatment and prevention of dengue virus infections | |
WO2020177128A1 (zh) | 2,6-二氮杂螺[3.4]辛烷类嘧啶-异羟肟酸化合物及其用途 | |
US20090209534A1 (en) | Novel compounds and use of tetrahydropyridopyridothiophenes | |
US20130053396A1 (en) | Piperidine and piperazine derivatives as smo antagonists | |
WO2012109573A1 (en) | Substituted thiazoles for use as antiviral agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |
Effective date: 20181206 |
|
FZDE | Discontinued |
Effective date: 20181206 |